Charles River Laboratories International, Inc.

  • Market Cap: Small Cap
  • Industry: Miscellaneous
  • ISIN: US1598641074
USD
184.04
-0.63 (-0.34%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Charles River Laboratories International, Inc. stock-summary
stock-summary
Charles River Laboratories International, Inc.
Miscellaneous
Charles River Laboratories International, Inc. is an early-stage contract research company. The Company is engaged in laboratory animal medicine and science (research model technologies) and develop a portfolio of discovery and safety assessment services, both good laboratory practice (GLP) and non-GLP, which supports its clients from target identification through non-clinical development. The Company operates in three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment includes Research Models and Research Model Services. The DSA segment includes Discovery Services and Safety Assessment. The Manufacturing segment includes Microbial Solutions, Avian, Biologics and Contract Manufacturing. The Company also provides a suite of products and services to support the Company's clients' manufacturing activities.
Company Coordinates stock-summary
Company Details
251 Ballardvale St , WILMINGTON MA : 01887-1096
stock-summary
Tel: 1 781 2226000
stock-summary
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Shareholding Compare (%holding) stock-summary
Majority shareholders

Domestic Funds

Domestic Funds

Held in 144 Schemes (51.7%)

Foreign Institutions

Held by 313 Foreign Institutions (26.7%)

Strategic Entities with highest holding

Highest Public shareholder

stock-summary Board of Directorsstock-summary
Management
Designation
Mr. James Foster
Chairman of the Board, President, Chief Executive Officer
Dr. George Milne
Lead Independent Director
Mr. George Llado
Director
Dr. Nancy Andrews
Independent Director
Mr. Robert Bertolini
Independent Director
Mr. Stephen Chubb
Independent Director
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
1,032 Million
(Quarterly Results - Jun 2025)
Net Profit:
53 Million
stock-summary
Industry

Miscellaneous

stock-summary
Market cap

USD 7,997 Million (Small Cap)

stock-summary
P/E

22.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.63

stock-summary
Return on Equity

8.57%

stock-summary
Price to Book

2.38